About Keratin, type I cytoskeletal 23
Keratin, type I cytoskeletal 23 (KRT23) is a protein
from Homo sapiens identified by UniProt accession
Q9C075, 422 residues long.
MolForge cross-references it against 0 known binders and
81 disease associations.
Target properties
| Protein name | Keratin, type I cytoskeletal 23 |
| UniProt accession | Q9C075 |
| Gene | KRT23 |
| Organism | Homo sapiens |
| Length | 422 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (81)
Diseases linked to this target (Open Targets).
- head and neck squamous cell carcinoma · score 0.19
- clear cell renal carcinoma · score 0.18
- glioblastoma multiforme · score 0.18
- prostate adenocarcinoma · score 0.18
- ovarian cancer · score 0.18
- breast adenocarcinoma · score 0.18
- mitochondrial DNA depletion syndrome 4a · score 0.07
- colorectal cancer · score 0.05
- metabolite measurement · score 0.04
- neoplasm · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9C075-F1 | alphafold | PREDICTED | 77.03 | — |
Amino-acid sequence (422 residues)
MNSGHSFSQT PSASFHGAGG GWGRPRSFPR APTVHGGAGG ARISLSFTTR SCPPPGGSWG SGRSSPLLGG NGKATMQNLN DRLASYLEKV RALEEANMKL ESRILKWHQQ RDPGSKKDYS QYEENITHLQ EQIVDGKMTN AQIILLIDNA RMAVDDFNLK YENEHSFKKD LEIEVEGLRR TLDNLTIVTT DLEQEVEGMR KELILMKKHH EQEMEKHHVP SDFNVNVKVD TGPREDLIKV LEDMRQEYEL IIKKKHRDLD TWYKEQSAAM SQEAASPATV QSRQGDIHEL KRTFQALEID LQTQYSTKSA LENMLSETQS RYSCKLQDMQ EIISHYEEEL TQLRHELERQ NNEYQVLLGI KTHLEKEITT YRRLLEGESE GTREESKSSM KVSATPKIKA ITQETINGRL VLCQVNEIQK HA
Explore Keratin, type I cytoskeletal 23 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets